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Abstract. Histone deacetylase enzymes (HDACs) are 
emerging as a promising biological target for cancer and 
inflammation. Using a fluorescence assay, we tested the 
in vitro HDAC inhibitory activity of twenty-one natural 
chalcones, a widespread group of natural products with 
well-known anti-inflammatory and antitumor effects. Since 
HDACs regulate the expression of the transcription factor 
NF-κB, we also evaluated the inhibitory potential of the 
compounds on NF-κB activation. Only four chalcones, 
isoliquiritigenin (no. 10), butein (no. 12), homobutein (no. 15) 
and the glycoside marein (no. 21) showed HDAC inhibitory 
activity with IC50 values of 60-190 µM, whereas a number 
of compounds inhibited TNFα-induced NF-κB activation 
with IC50 values in the range of 8-41 µM. Interestingly, three 
chalcones (nos. 10, 12 and 15) inhibited both TNFα-induced 
NF-κB activity and total HDAC activity of classes I, II and 
IV. Molecular modeling and docking studies were performed 
to shed light into dual activity and to draw structure-activity 
relationships among chalcones (nos. 1-21). To the best of our 
knowledge this is the first study that provides evidence for 
HDACs as potential drug targets for natural chalcones. The 
dual inhibitory potential of the selected chalcones on NF-κB 
and HDACs was investigated for the first time. This study 
demonstrates that chalcones can serve as lead compounds in 
the development of dual inhibitors against both targets in the 
treatment of inflammation and cancer.
Introduction
Acetylation is a pivotal post-transcriptional modification, 
which strongly influences chromatin structure and function 
(1). Due to its wide variety of targets, it is not only implicated 
in the regulation of gene expression via chromatin structure 
modifications but also in protein-protein interactions, protein 
stability, DNA binding, and subcellular localization (2). Histone 
acetylation is mediated by histone acetyltransferases (HATs). 
The resulting structural modification of chromatin leads to 
nucleosomal relaxation and altered transcriptional activation. 
The reverse reaction is mediated by histone deacetylases 
(HDACs), which induce deacetylation, chromatin condensa-
tion, and transcriptional repression (3). Alterations mediated 
by HAT/HDAC activities are not solely reduced to chromatin. 
Mounting evidence accentuates their involvement in lysine 
acetylation/deacetylation of non-histone substrates including 
transcription factors (such as NF-κB, p53, GATA2, MEF2) and 
chromatin-associated co-repressor proteins (4,5). A balanced 
histone acetylation status is essential for the proper progress of 
cell proliferation, apoptosis and differentiation. An improper 
HDAC recruitment or activity, often leads to abnormal gene 
expression that is associated with cancer development (6), 
hence rendering HDAC as an excellent target in current cancer 
research. Two HDAC inhibitors, suberoylanilide hydroxamic 
acid (SAHA; vorinostat) and the natural product romidepsin 
(FK-228) are currently approved for cancer chemotherapy and 
many other inhibitors are in clinical trials (7). So far, eighteen 
human HDAC enzymes have been identified and grouped into 
four classes based on the structure of their accessory domains. 
Classes I, II, and IV, but not III, require a zinc molecule as 
an essential cofactor in their active site and are inhibited by 
Zn2+-binding HDAC inhibitors such as SAHA and the natural 
product, trichostatin A. Class I HDACs comprise HDACs 
1, 2, 3 and 8, whereas class II HDACs include HDACs 4, 5, 
6, 7 and 9 that are larger in size than the other classes (4,5). 
Recent publication of the X-ray crystal structure of HDAC8 
(8) followed by several other HDACs (7) fuelled the research 
activity in the discovery and development of novel HDAC 
inhibitors.
The transcription factor NF-κB is a dimer of proteins 
belonging to the Rel family. It is an ubiquitous transcrip-
tion factor present in all cell types. The most common form 
of NF-κB is the p65/p50 heterodimer. In most cells, NF-κB 
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complexes are localized to the cytosol as inactive forms 
with the inhibitor of κB protein (IκB). Phosphorylation of 
IκB results in its ubiquitination and subsequent proteasome-
mediated degradation. Activated NF-κB then translocates to 
the nucleus where it transactivates more than 500 target genes 
(9). Many factors are known to activate NF-κB, including 
inflammatory cytokines such as tumor necrosis factor alpha 
(TNFα) and interleukin (IL)-1, carcinogens (cigarette smoke), 
UV radiation, hyperglycemia and tumor promoters. Over the 
last decade, NF-κB became a major target in drug discovery, 
due to its key role in cancer development, inflammation, cell 
proliferation and death (10).
Recent evidence indicates that the activation of various 
transcription factors, including NF-κB, is regulated through 
the interaction with HDAC proteins (11-13). Previous studies 
with various cell types showed that HDAC1 and HDAC2 
negatively regulate NF-κB activity through direct interaction 
with the p65 (RelA) subunit of NF-κB (14,15). Other studies 
suggest a physical interaction between p65 (RelA) and class I 
type HDACs (HDAC1, 2 and 3), where high expression of class 
I HDACs has been linked to increased nuclear translocation of 
p65 (RelA) (16). Remarkably, Class I HDAC isoforms are often 
overexpressed in various types of cancers where they are usually 
associated with a poor prognosis (5,17,18). In addition, HDAC 
inhibitors are acknowledged as effective anti-inflammatory 
agents, some inhibiting NF-κB (19-21) and may therefore play 
an important role in the prevention of cancers that develop as 
a result of chronic inflammation. The combined antiprolifera-
tive as well as anti-inflammatory potency represents a highly 
attractive combination for the treatment of numerous chronic 
inflammatory conditions which are frequently associated with 
an increased risk of developing cancer.
Chalcones (1,3-diphenyl-2-propenones) are a group of 
aromatic compounds that represent a large class of natural 
products found in many medicinal plants, fruits, vegetables, 
spices and nuts. They are the natural precursors of flavonoids 
and display a variety of biological activities. Although the 
modes of action of this class of compounds are not fully 
understood, great efforts are devoted to elucidate the mecha-
nisms underlying their promising anti-inflammatory and 
anticancer activities. Hence several natural chalcones have 
been reported to inhibit the NF-κB signaling, and numerous 
synthetic derivatives have been evaluated in structure-activity 
relationship (SAR) studies (22,23). Besides the NF-κB inhi-
bition, interference in microtubule formation is generally 
thought to be responsible for their anticancer activities (24,25). 
Despite the cross-talk and modulation effects between NF-κB 
and HDACs, and structural similarity of chalcones to broad-
spectrum HDAC inhibitors SAHA and trichostatin A, HDACs 
have not been investigated as potential targets for natural chal-
cones. In this study, we aimed to test twenty-one commercially 
available chalcones (Table I) for dual HDACs and NF-κB 
inhibitory activities in vitro. Viability assays were also carried 
out to elucidate the cytotoxic potential of the chalcones against 
leukemia cells. We also aimed to explore SAR to determine 
the essential functionalities on the chalcone core for biological 
activity. We also performed molecular modeling and docking 
studies in an attempt to understand the potential mode and 
mode/site of binding of natural chalcones to NF-κB and class I 
type HDACs.
Materials and methods
Chalcones. Twenty-one natural chalcones, namely chalcone, 
2'-hydroxychalcone, 2-hydroxychalcone, 4-hydroxychal-
cone, 4 -methoxychalcone, 3,4 -dimethoxy chalcone, 
4'-hydroxychalcone, 4'-methoxychalcone, 4,4'-dime-
thoxychalcone, isoliquiritigenin (2',4,4'-trihydroxy chalcone), 
calomelanone (2',6'-dihydroxy-4,4'-dimethoxydihydrochal-
cone), butein (2',3-4,4'-tetrahydroxychalcone), flavokawain 
C (2',4-dihydroxy-4',6'-dimethoxychalcone), gymno-
grammene (2',6'-dihydroxy-4,4'-dimethoxychalcone), 
homobutein (2',4,4'-t r ihydroxy-3-methoxychalcone), 
2,3-dimethoxy-2'-hydroxychalcone, f lavokawain A 
(2'-hydroxy-4,4',6'-trimethoxychalcone), eriodictyolchalcone 
(2',4',6',3,4-pentahydroxychalcone) phloretin (2',4,4',6'-tetrahy-
droxydihydrochalcone), phloridzin (phloretin-2'-O-glucoside) 
and marein (2',3,3',4,4'-pentahydroxy-4'-glucosylchalcone) 
were studied. Table 1 shows their chemical features and substi-
tution patterns. Chalcone was purchased from Fluka 
(Steinheim, Germany), whereas all remaining chalcones were 
obtained from Extrasynthese (Genay Cedex, France) (purity 
>97%).
Cell culture and reagents. Human Philadelphia chromosome-
positive chronic myelogenous leukemia cell line K562 was 
purchased from Deutsche Sammlung für Mikroorganismen 
und Zellkulturen (DSMZ, Braunschweig, Germany) and 
cultured in RPMI-1640 medium (Lonza, Verviers, Belgium) 
supplemented with 10% fetal calf serum (Hyclone, Perbio, 
Erembodegem, Belgium) and 1% (v/v) antibiotic-antimycotic 
(Lonza, BioWhittaker™), at 37˚C, in a 5% CO2, humidified 
atmosphere. Human recombinant TNFα (PeproTech, Rocky 
Hill, NJ, USA) was resuspended in 1X phosphate-buffered 
saline (PBS) sterile solution containing 0.5% bovine serum 
albumin (MP Biomedicals, Asse-Relegem, Belgium) to reach 
a final concentration of 10 µg/ml.
HDAC activity/inhibition measurement. Direct HDAC inhibi-
tion by chalcone derivatives was estimated using K562 total 
extracts as an HDAC source and the enzymatic HDAC activity 
measurement was performed using a fluorometric HDAC 
assay kit (Active Motif, Rixensart, Belgium) according to the 
manufacturer's instructions. Briefly, after being washed twice 
with ice-cold 1X PBS, cells were pelleted by centrifugation, 
and lysed in M-PER® mammalian protein extraction reagent 
(Pierce, Erembodegem, Belgium) and supplemented with 1X 
protease inhibitor cocktail (Roche, Prophac, Luxembourg). 
The cell suspension was gently mixed on an orbital shaker 
for 15 min and centrifuged at 14,000 x g at 4˚C for 15 min. 
Protein content was assessed using the Bradford assay (Bio-
Rad, Nazareth, Belgium), and 10 µg of proteins were incubated 
with vehicle or various concentrations of the different chal-
cones for 1 h at 37˚C in the presence of an HDAC fluorometric 
substrate. Subsequently, the HDAC assay developing solution 
was added and after 15 min of incubation at room temperature, 
the fluorescence was measured using a Gemini EM micro-
plate spectrofluorometer (Molecular Devices, Belgium) with 
excitation at 360 nm and emission at 460 nm. The measured 
activities were normalized by the vehicle-treated control 
enzyme activities and IC50 values were calculated.
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Transient transfections. Transient transfections of K562 cells 
were performed as previously described (26).
In vitro cytotoxicity assays (viability assay). The in vitro 
growth inhibitory values of chalcone derivatives on the K562 
cell line were determined as detailed previously (26).
Molecular modeling and docking studies. The 2D struc-
tures of chalcone molecules were drawn using SketchEI and 
transferred into the VEGA ZZ molecular modeling software 
(27,28) to generate 3D structures. All molecules were saved 
into a single mol file, that was used as input for the OMEGA, 
OpenEye Scientific Software (Omega version 2.3.2; http://
www.openeye.com) to generate a maximum of 2 low energy 
conformers with default values. These conformations were 
stored as OEB file extension format and their 3D similarity was 
compared using the Rocs, OpenEye Scientific Software (Rocs 
version 2.3.1; http://www.openeye.com). E-Dragon Software 
(29) was utilized to calculate constitutional and molecular 
property descriptors. The descriptors selected to describe the 
SAR were selected using Partial Least Squares regression as 
implemented in the PLSR module of Virtual Computational 
Chemistry Laboratory (29) and Gretl software was used to 
calculate the correlation between the logarithm of the activity 
and predicted molecular properties. 
The molecular docking was carried out using Glide software 
(Grid-Based Ligand Docking With Energetics) (Schrodinger 
Inc., Portland, OR, USA) (30,31) after the docking targets 
were prepared using Protein Preparation Wizard workflow 
in Maestro (Schrodinger Inc.) by removing water molecules, 
adding the hydrogen atoms and assigning all atom force field 
(OPSL-2005) charges and atom types. The position of all 
atoms was adjusted by minimizations until the average root 
mean square deviation reached 0.3 Å. The crystal structures 
of HDAC8 wild-type and variant D101 complexed with ligands 
[Protein Data Bank (pdb) entries 1T69 and 3EZT] were used 
for molecular docking of chalcones into the protein active site. 
The box encompassing the active site was selected based on the 
position of co-crystalized ligands complex as described in a 
previous study (32). The crystal structure of NF-κB complexed 
to DNA was chosen as a target system to elucidate binding 
modes of chalcones (pdb entry 1NFK). Prior to docking 
the DNA molecule was removed and the coordinates of the 
enclosing box of 30 Å (center at x = -1,1958 Å; y = 9.0149 Å; z = 
19,7598 Å) were encompassing the active site residues involved 
in hydrogen bonds with the NF-κB recognition site of DNA 
(Arg54, Arg56, Tyr57, Cys59, Lys241, Gln306 and Thr143) 
(35). Flexible ligand docking simulations were carried out with 
Glide using the default settings. The ten best poses obtained 
using the Extra-Precision Glide (Glide XP) mode were selected 
for analysis. The most favorable poses of molecules showing 
activity were subjected to further energy minimization using 
Macromodel 9.1 and OPLS2005 force field.
Results
Inhibition of HDAC activity by chalcone derivatives. The 
effect of chalcone derivatives (nos. 1-21) was examined on total 
Figure 1. Inhibition of HDAC activity by active chalcone derivatives. Total protein extracts from K562 cells were incubated with vehicle (0) or various con-
centrations of the (A) chalcone 10 (B) chalcone 12 (C) chalcone 15 or (D) chalcone 21 for 1 h in the presence of an HDAC fluorometric substrate. Fluorescence 
was measured using a Gemini EM microplate spectrofluorometer and normalized by the vehicle-treated control enzyme activities. Vehicle-treated control 
corresponds to 0 on the chart. Results are presented as a mean ± SD of at least three independent experiments. 
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HDAC activity using a fluorescence HDAC assay. As shown 
in Table II, four chalcone aglycones, namely isoliquiritigenin 
(no. 10), butein (no. 12), homobutein (no. 15) and the glycoside 
marein (no. 21), reduced HDAC activity in a concentration-
dependent manner (IC50 values 60-190 µM, Fig. 1). Butein 
(no. 12) appeared to be the best inhibitor of HDAC activity. 
Other chalcone derivatives were assumed as inactive, because 
they were unable to provide distinct inhibitory effect even at 
the highest test concentration (1000 µM).
Inhibition of TNFα-induced NF-κB activation by chalcones. 
By using a luciferase-based in cellulo NF-κB reporter 
assay, chalcones were evaluated for TNFα-induced NF-κB 
transcription inhibition activity (Table II). Flavokawain C 
(no. 13) was the most potent NF-κB inhibitor, followed by the 
dihydrochalcone calomelanone (no. 11) with IC50 values of 8 
and 11 µM, respectively (Fig. 2). Chalcones 4-hydroxychal-
cone (no. 4), 4-methoxychalcone (no. 5), 4'-hydroxychalcone 
(no. 7), isoliquiritigenin (no. 10), butein (no. 12), homobutein 
(no. 15) and phloretin (no. 19) also demonstrated good 
potential with IC50 values ranging between 24-41 µM. Three 
polymethoxychalcones, i.e. 4,4'-dimethoxychalcone (no. 9), 
gymnogrammene (no. 14), flavokawain A (no. 17), as well as 
cone eriodictyolchalcone (no. 18) and two chalcone glycosides, 
phloridzin (no. 20) and marein (no. 21), which showed no or 
limited inhibitory activity at 200 µM concentration, were 
considered as inactive. The remaining compounds, chalcone 
(no. 1), 2'-hydroxychalcone (no. 2), 2-hydroxychalcone (no. 3), 
3,4-dimethoxychalcone (no. 6), 4'-methoxychalcone (no. 8) 
and 2,3-dimethoxy-2'-hydroxychalcone (16) were cytotoxic at 
concentrations, which inhibited NF-κB activation.
Docking studies of chalcones 12 and chalcone 21 within the 
active site of HDAC8. In order to shed light on the potential 
mode of action of chalcones, and to understand why some 
chalcones inhibit either NF-κB or HDACs and some inhibit 
both, we have carried out molecular modeling, molecular 
similarity and docking studies. The compounds were docked 
into the binding sites of HDAC8, and the best studied HDAC 
enzyme was selected based on the position of the co-crystal-
ized ligand in the crystal structure of the complex (pdb entries 
1T69 and 3ETZ) (32). The GlideScore values were compared 
to the activities that were experimentally obtained (Table III). 
Table II. Biological activity of natural chalcones.
 HDAC NF-κB
 inhibition, inhibition,
Chalcone IC50 (µM) IC50 (µM) Viability
  1 >1000 n.m. 14
  2 >1000 n.m. 28
  3 >1000 n.m. 2
  4 >1000 24 31
  5 >1000 29 35
  6 >1000 n.m. 38
  7 >1000 28 16
  8 >1000 n.m. 38
  9 >1000 >200 n.t.
10 110 32 44
11 >1000 11 31
12 60 38 13
13 >1000 8 13
14 >1000 >200 n.t.
15 190 38 29
16 >1000 n.m. 12
17 >1000 >200 n.t.
18 >1000 >200 n.t.
19 >1000 41 59
20 >1000 >200 n.t.
21 100 >200 n.t.
Standards 0.14b 6.0a  1.4a 
n.m., not measurable due to toxicity after transfection; n.t., not tested 
due to the inability to inhibit the activation of NF-κB; Standards, 
aheteronemin, bsuberoylanilide hydroxamic acid. 
Figure 2. Inhibition of TNFα-induced NF-κB activation by (A) chalcone 11 and (B) chalcone 13. K562 cells were transiently transfected with firefly luciferase 
vector (NF-κB pGL4), and ph-RG-tk Renilla plasmid for 24 h. After transfection, K562 cells were treated with chalcone derivatives at the different concentra-
tions for 2 h followed by a TNFα-treatment (20 ng/ml) during 6 h. Results are expressed as a ratio of the measured luminescence of the firefly luciferase vector 
and the luminescence of Renilla plasmid. Results are presented as a mean ± SD of three independent experiments. Negative control (Co-) corresponds to 
DMSO treated cells, without TNFα activation, positive control (Co+) corresponds to DMSO treated cells activated by TNFα.
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The results of the docking indicated that all chalcones could 
favorably bind in the active site, although not all molecules 
showed activity. The most active molecule 12 had a less favor-
able GlideScore than chalcone 21 that exhibited the most 
favorable binding. The binding mode of these two molecules 
is different (Fig. 3) which may be the result of the large active 
site of HDAC8 which accommodates two (4-(dimethylamino)-
N-[7-(hydroxyamino)-7-oxoheptyl]benzamide) moieties in the 
interior pocket of the protein. Furthermore, the docking could 
not distinguish the third active molecule 10 from the rest of the 
group. There is a clear difference between the GlideScore of 
the binding of 21 to 20. However, 20 binds almost as good as 12 
and better than 10, resulting in the absence of the correlation 
between activity and binding affinity determined by Glide. We 
hypothesize that molecules that are not active could possibly 
bind preferably elsewhere on the protein surface rather than on 
the active site.
The docking studies of chalcones were also carried out 
using a crystal structure of NF-κB dimer in complex with 
duplex DNA. We followed a procedure reported by Piccagli 
et al (33) and have chosen the DNA recognition surface to 
define the docking target. The binding site included residues 
Arg54, Arg56, Tyr57, Cys59, Lys241, Gln306 and Thr143 to 
gain information on the interaction of our compounds with 
NF-κB. As shown in Table III, there is a lack of correlation 
between the activity and the GlideScore results. This can be 
due to non-specific binding. Moreover, chalcones could act 
on a different active site of NF-κB. To further rationalize the 
activity of this class of compounds we have elucidated the 
SARs and predicted more than 1600 molecular properties for 
all molecules using EDragon software (29). This analysis was 
not aimed to lead to the development of predictive models 
since the data set is small (fifteen molecules with measured 
NF-κB activity) and thus we did not create training and test 
sets. Two different sets of molecules were subjected to partial 
least square regression using PLSR module of the Virtual 
Computational Chemistry Laboratory to determine which 
constitutional and molecular properties correlated with the 
negative logarithm of activity (pNF-κB). The first group 
consisted of all fifteen tested molecules and the observed corre-
lation was not satisfactory (r2=0.53), leading us to examine the 
second smaller group, consisting of only nine molecules that 
displayed activity. The PLS results indicated that a combina-
tion of nineteen descriptors correlated with activity (r2=0.99). 
There were some highly correlated and irrelevant descriptors 
selected to describe correlation. The selection of descriptors 
was optimized by developing least square methods using 
the Gretl software and removing descriptors until a minimal 
number of descriptors was obtained with a good correlation 
(r2= 0.914, s=0.250, n=9, F=3.48). The formula used was the 
following: pNF-κB = -79.78(±48.55) - 0.425(±.0.344)*SS + 
31.582(±24.)*Mp + 43.847(±25.978)*ARR + 1.868 (±1.619)*Hy 
+ 0.265(±.468)*MLOGP + 2.793 (±1.682)*nBO.
The list and values of descriptors, observed and calculated 
are shown in Table IV. The statistics indicate reasonable 
descriptive value of the model that shows which molecular 
properties influence activity of the molecules in the NF-κB 
assay. Since we could not develop a satisfactory model that 
would differentiate the active and inactive molecules, we 
examined the molecular similarity and differences between 
most active molecules and the inactive ones. Conformational 
search carried out by Omega software and the Merck Molecular 
Force Field force revealed that all molecules can exist in 
several different conformations due to the free rotation around 
bonds between carbonyl carbon  and neighboring groups. 
ROCS search and comparison of electrostatic forces showed 
that unsurprisingly molecules are similar (Shape Tanimoto 
coefficients are between 0.94 and 0.0.69 and Tverstsky coef-
ficients are between 0.91 and 0.71). The highest similarity was 
Table III. GlideScore values obtained for HDAC and NF-κB 
proteins.
 Docking scores Docking scores Docking scores
Chalcone against 1T69  against 3ETZ against 1NFK
  1 -6.83 -5.27 -2.39
  2 -5.90 -6.08 -4.05
  3 -5.40 -6.35 -3.06
  4 -4.71 -6.27 -2.38
  5 -5.52 -5.34 -3.22
  6 -4.92 -5.87 -2.76
  7 -4.88 -5.96 -2.88
  8 -5.78 -5.86 -2.48
  9 -5.88 -5.70 -2.6
10 -6.03 -7.03 -2.84
11 -6.75 -7.21 -3.15
12 -7.00 -8.00 -4.71
13 -5.32 -7.45 -3.48
14 -5.63 -6.52 -4.29
15 -6.44 -7.06 -0.71
16 -5.31 -6.57 -3.1
17 -4.47 -6.79 -1.75
18 -5.69 -7.24 -4.06
19 -5.15 -6.47 0.12
20 -6.85 -7.57 -5.53
21 -8.08 -10.51 -6.03
Figure 3. Best binding poses of chalcone 12 (thick stick representation) and 
chalcone 21 (thin stick representation) within the active site of the HDAC8 
represented by surface only. The docking was carried out using Glide and DS 
Visualizer 3.1 was used to prepare the image.
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observed between the most active chalcone molecule 13 and 
inactive 9, indicating that shape and electrostatic properties 
are not sufficient to explain the different activities of the group.
Discussion
Chronic inflammation has been linked to most incurable 
illnesses, including cancer, cardiovascular and neurodegen-
erative diseases. Cancer is regulated by a large number of 
genes that are modulated by transcription factors, such as 
NF-κB, which controls genes involved in inflammation, 
proliferation, angiogenesis and metastasis (23). Any distur-
bance in the corresponding pathways leads to the activation 
of NF-κB and release of cytokines, thus contributing to the 
initiation and progression of tumorigenesis. On the other hand, 
acetylation and deacetylation act as regulating mechanisms 
for activation or inactivation of various transcription factors, 
including NF-κB. This process is mediated by HDAC and can 
consequently be modulated by HDAC inhibitors (34). Protein 
complexes involved in the regulation of cell-cycle progres-
sion and apoptosis are also controlled by this mechanism (2). 
The reversible acetylation appears to regulate the interaction 
between p65 and IκB, and controls the duration of the NF-κB 
response. NF-κB activation leads to apoptosis resistance. 
Several NF-κB inhibitors showed potential to overcome this 
resistance and induce apoptosis (35,36). Thus, inhibition of 
NF-κB may sensitize cancer cells and eventually lead to the 
induction of apoptosis. Interestingly, in our study, chalcones 
4, 5, 7, 10, 11, 12, 13, 15 and 19 inhibited both NF-κB and the 
viability of K562 cells. 
Interestingly, three chalcones (nos. 10, 12, and 15) inhib-
ited both NF-κB and HDAC activity. Nevertheless, underlying 
mechanisms in the action of chalcones as dual inhibitors 
remain to be elucidated in the future. To our knowledge, the 
mechanisms that link both inhibitory activities were first 
reported herein. As an example, upon interaction with histone 
deacetylase 3 (HDAC3), p65 is deacetylated leading to effi-
cient interaction with IκB and subsequent activation via the 
canonical pathway (37). Compounds that efficiently inhibit 
HDAC3 and other HDAC isoforms are considered interesting 
NF-κB inhibitors. Moreover, transcription factor STAT1 
is physiologically acetylated and binds p65, thus inhibiting 
NF-κB. STAT1-associated HDAC were described to deacety-
late STAT1 leading to the liberation of p65 and subsequent 
activation of the canonical NF-κB pathway. Inhibitors of 
HDAC activity contribute to a shift towards acetylated STAT1 
actively interacting with NF-κB and thus inhibiting activation 
of p65 required for inflammatory cell signaling (38). Even 
though the inhibitory activity of selected chalcones appears 
weak when only the total HDAC activity is assessed, inhibitory 
effect against specific HDAC isoforms are generally stronger 
as shown for tubastatin A (39).
Attempts to generate HDAC inhibitors generally focus 
on varying the cap group to exploit variability in the HDAC 
surface surrounding the active site. However, although efforts 
are being made to identify truly class- or isoform-selective 
HDAC inhibitors with anticancer and anti-inflammatory 
properties, the current list of such compounds remains rela-
tively poor. One of the main reasons is the lack of structural 
determinants of selective HDAC inhibition due to the chal-
lenge of studying the interaction of small inhibitory molecules 
with multiple large protein complexes that encompass HDAC 
activities, which are often dependent on or regulated by these 
complexes. Accordingly, the selectivity of small inhibitory 
molecules may depend on the context of HDAC complexes and 
requires investigation (40). The small size of the library limits 
the ability to obtain common structural features necessary for 
individual or dual target activity.
A number of SAR studies have been performed on synthetic 
chalcones and their biological effects, including NF-κB inhibi-
tion (22,23). To our knowledge this is the first study looking at 
potential SARs among natural chalcones. In the present study, 
some chalcones showed interesting NF-κB inhibitory poten-
tial, and some empirical SARs have been obtained. Our results 
show that chalcone, the parent compound, or its 2'-hydroxy- or 
2-hydroxy- derivatives (nos. 1-3) did not express any NF-κB 
inhibition potential. We were able to draw some SARs 
originating from the substitutions with an electron donating 
Table IV. Predicted molecular properties correlating to the activity of potent chalcones in the NF-κB assay.
Chalcone Ss Mp nBO Hy MLOGP ARR Observed Calculated   
       pNF-κB pNF-κB
  4 41.67 0.71 18 -0.371 3.148 0.667 4.62 4.59
  5 41.17 0.69 19 -0.873 3.398 0.632 4.54 4.56
  7 41.67 0.71 18 -0.371 3.148 0.667 4.55 4.59
10 53.00 0.69 20 1.096 2.552 0.600 4.49 4.37
11 56.67 0.65 23 0.304 2.334 0.522 4.96 4.97
12 58.67 0.68 21 1.928 1.764 0.571 4.42 4.51
13 57.67 0.67 23 0.304 1.746 0.522 5.10 5.02
15 58.17 0.67 22 0.545 1.062 2.013 4.42 4.51
19 58.67 0.68 21 1.928 1.764 0.571 4.39 4.40 
Ss, Sum of Kier-Hall electrotopological states; Mp, mean atomic polarizability (scaled on Carbon atom); nBO, number of non-H bonds; Hy, 
hydrophilic factor; MLOGP, Moriguchi octanol-water partition coefficient (logP); ARR, aromatic ratio; pNF-κB, negative logarithm values of 
activity observed in NF-κB assay.
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functional group such as methoxy or hydroxy, at positions 4, 
4' and 6'. Chalcone glycosides (nos. 20 and 21) were not active, 
which might be due to the reduced permeability through cell 
membranes. In addition, all chalcones with reported NF-κB 
activity contain a highly electrophilic α,β-unsaturated carbonyl 
moiety and calomelanone and phloretin are the first examples 
of dihydrochalcones with such activity. For HDAC activity 
clearer trends were observed, i.e. hydroxy groups at C-2', C-4', 
C-3 and C-4 were essential. This substitution pattern also 
appears to be important for dual activity. The empirical SARs 
prompted us to perform some molecular modeling-docking 
studies on both targets. The molecular modeling investiga-
tions could not provide a definite rationale for dual activity of 
chalcones and failed to provide criteria for distinguishing the 
active molecules from inactive. There could be many reasons 
underlying this observation. Most of the molecules have low 
molecular weight (between 200 to 275 Da) and as such can 
be considered as fragments. This could lead to non-specific 
binding and lack of correlation between molecular properties 
and activity. 
Some of the compounds tested herein have previously 
been reported as NF-κB inhibitors including isoliquiritigenin 
(no. 10) (41) and butein (no. 12) (42). We have previously 
demonstrated that 4'-hydroxychalcone showed 26S protease 
inhibition activity on three different proteolytic activities 
(chymotrypsin, trypsin- and caspase-like) in a dose-dependent 
manner (26). The involvement of natural chalcones in cancer 
tumorigenesis has been reviewed (43). To the best of our 
knowledge this is the first study aiming to screen a natural 
chalcone library and attempting to draw SARs among them. 
Several natural chalcones emerged as relatively good inhibi-
tors of NF-κB. Additionally, HDAC was identified as a novel 
potential target for the chalcones described.
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